G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study

Yan-Ru Ma, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo, Yan-Ru Ma, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo

Abstract

G-CSF-mobilized peripheral blood (G-PB) harvest is the predominant graft for identical sibling donor and unrelated donor allogeneic hematopoietic stem cell transplantation (HSCT) recipients, but it was controversial in haploidentical related donor (HID) HSCT. In this registry study, we aimed to identify the efficacy of HID G-PB HSCT (HID-PBSCT) for acute leukemia (AL) patients in first complete remission (CR1). Also, we reported the outcomes for the use of G-PB grafts in comparison with the combination of G-BM and G-PB grafts in HID HSCT recipients. Sixty-seven AL patients in CR1 who received HID-PBSCT were recruited at Institute of Hematology, Peking University. Patients who received haploidentical HSCT using the combination of G-BM and G-PB harvests in the same period were enrolled as controls (n=392). The median time from HSCT to neutrophil and platelet engraftment was 12 days (range, 9-19 days) and 12 days (range, 8-171 days), respectively. The 28-day cumulative incidence of neutrophil and platelet engraftment after HSCT was 98.5% and 95.5%, respectively. The cumulative incidences of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) were 29.9% (95%CI 18.8-40.9%) and 7.5% (95%CI 1.1-13.8%), respectively. The cumulative incidences of total and moderate-severe chronic GVHD were 54.9% (95%CI 40.9-68.8%) and 17.4% (95%CI 6.7-28.0%), respectively. The cumulative incidences of relapse and non-relapse mortality were 13.9% (95%CI 5.4-22.5%) and 3.4% (95%CI 0-8.1%), respectively. The probabilities of overall survival (OS) and leukemia-free survival (LFS) were 84.7% (95%CI 74.7-94.7%) and 82.7% (95%CI 73.3-92.1%) respectively. Compared with the HID HSCT recipients using the combination of G-BM and G-PB grafts, the engraftments of neutrophil and platelet were both significantly faster for the G-PB group, and the other clinical outcomes were all comparable between the groups. In multivariate analysis, graft types did not influence the clinical outcomes. Overall, for the patients with AL CR1, G-PB graft could be considered an acceptable graft for HID HSCT recipients. This study was registered at https://ichgcp.net/clinical-trials-registry/NCT03756675" title="See in ClinicalTrials.gov">NCT03756675.

Keywords: acute leukemia; complete remission (CR); haploidentical donor; peripheral blood (PB); stem cell transplant (SCT).

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Ma, Zhang, Xu, Wang, Yan, Chen, Chen, Han, Wang, Wang, Liu, Huang and Mo.

Figures

Figure 1
Figure 1
CONSORT (the Consolidated Standards of Reporting Trials) Flow Diagram Showing the Study Design of the trial.
Figure 2
Figure 2
Comparison between G-PB and G-BM plus PB groups (A). Relapse; (B). NRM; (C). Overall survival; and (D). Leukemia-free survival.

References

    1. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. . Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood (2000) 95(12):3702–9. 10.1182/blood.V95.12.3702
    1. Zhao XS, Chen Y, Zhao XY, Liu DH, Xu LP, Wang Y, et al. . Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. Clin Transplant (2013) 27(6):844–51. 10.1111/ctr.12225
    1. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al. . A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood (2002) 100(5):1525–31. 10.1182/blood-2002-01-0048
    1. Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, et al. . Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood (2012) 119(11):2675–8. 10.1182/blood-2011-12-396275
    1. Ringden O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, et al. . Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Internal Med (2012) 272(5):472–83. 10.1111/j.1365-2796.2012.02547.x
    1. Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, et al. . Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 18(9):1422–9. 10.1016/j.bbmt.2012.02.013
    1. Sanz J, Galimard J-E, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. . Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol (2020) 13(1):46. 10.1186/s13045-020-00882-6
    1. Zhao X, Gao F, Zhang X, Wang Y, Xu L, Liu K, et al. . Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Sci China Life Sci (2016) 59(11):1139–48. 10.1007/s11427-016-0014-8
    1. Xu LP, Liu KY, Liu DH, Chen H, Han W, Chen YH, et al. . The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant (2010) 45(6):985–92. 10.1038/bmt.2009.311
    1. Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, et al. . Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia (2020) 34(10):2766–75. 10.1038/s41375-020-0850-9
    1. O’Donnell PV, Eapen M, Horowitz MM, Logan BR, DiGilio A, Brunstein C, et al. . Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplant (2016) 51(12):1599–601. 10.1038/bmt.2016.215
    1. Bradstock K, Bilmon I, Kwan J, Blyth E, Micklethwaite K, Huang G, et al. . Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors. Biol Blood Marrow Transplant (2015) 21(9):1641–5. 10.1016/j.bbmt.2015.06.006
    1. Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, et al. . Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. Biol Blood Marrow Transplant (2019) 25(9):1810–7. 10.1016/j.bbmt.2019.05.017
    1. Chang YJ, Zhao XY, Huang XJ. Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Front Immunol (2019) 10:2516. 10.3389/fimmu.2019.02516
    1. Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang X-J, et al. . The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant (2020) 55(1):12–24. 10.1038/s41409-019-0499-z
    1. Lv M, Chang YJ, Huang XJ. Update of the “Beijing Protocol” haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplant (2019) 54(Suppl 2):703–7. 10.1038/s41409-019-0605-2
    1. Lv M, Chang Y, Huang X. Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Front Med (2019) 13(1):45–56. 10.1007/s11684-017-0595-7
    1. Luo L, Fang S, Zhao S, Li F, Zhou Y, Guan L, et al. . Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience. Ann Transplant (2019) 24:367–73. 10.12659/AOT.915182
    1. Wang F, Liu T, Wang L, Gu Z, Yang N, Luo L, et al. . Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission. Leuk Lymphoma (2020) 61(1):118–27. 10.1080/10428194.2019.1660965
    1. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. . Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood (2015) 125(25):3956–62. 10.1182/blood-2015-02-627786
    1. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et al. . Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer (2013) 119(5):978–85. 10.1002/cncr.27761
    1. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. . Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant (2006) 38(4):291–7. 10.1038/sj.bmt.1705445
    1. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. . Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant (2009) 15(2):257–65. 10.1016/j.bbmt.2008.11.025
    1. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. . Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. Biol Blood Marrow Transplant (2017) 23(12):2143–50. 10.1016/j.bbmt.2017.08.026
    1. Mo X-D, Zhang Y-Y, Zhang X-H, Xu L-P, Wang Y, Yan C-H, et al. . The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Sci Bull (2018) 63(20):1376–82. 10.1016/j.scib.2018.08.008
    1. Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W, et al. . Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol (2015) 8:84. 10.1186/s13045-015-0182-9
    1. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 15(6):825–8.
    1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 11(12):945–56. 10.1016/j.bbmt.2005.09.004
    1. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. . Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers. N Engl J Med (2001) 344(3):175–81. 10.1056/NEJM200101183440303
    1. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. . Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 367(16):1487–96. 10.1056/NEJMoa1203517
    1. Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, et al. . Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol (2017) 35(26):3002–9. 10.1200/JCO.2017.72.8428
    1. Ruggeri A, Labopin M, Bacigalupo A, Gulbas Z, Koc Y, Blaise D, et al. . Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer (2018) 124(7):1428–37. 10.1002/cncr.31228
    1. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, et al. . Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol (2010) 11(4):331–8. 10.1016/S1470-2045(09)70352-3
    1. Liu SN, Zhang XH, Xu LP, Wang Y, Yan ZH, Chen H, et al. . Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. Am J Hematol (2020) 95:(8):927–36. 10.1002/ajh.25839
    1. Mo XD, Xu LP, Zhang XH, Liu DH, Wang Y, Chen H, et al. . Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant (2015) 50(1):127–33. 10.1038/bmt.2014.223
    1. Weisdorf D, Zhang M-J, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning. Biol Blood Marrow Transplant (2012) 18(11):1727–33. 10.1016/j.bbmt.2012.06.014
    1. Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B, et al. . Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant (2014) 20(5):724–9. 10.1016/j.bbmt.2014.02.001
    1. Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, et al. . Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant (2020) 26(8):1459–68. 10.1016/j.bbmt.2020.05.001
    1. Mo X-D, Xu L-P, Zhang X-H, Liu D-H, Wang Y, Chen H, et al. . Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups. Int J Cancer (2015) 136(7):1697–707. 10.1002/ijc.29146
    1. Wang Y, Liu Q-F, Xu L-P, Liu K-Y, Zhang X-H, Ma X, et al. . Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clin Cancer Res (2016) 22(14):3467–76. 10.1158/1078-0432.CCR-15-2335

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться